Back to search

Boston University

Familial hypobetalipoproteinemia and abetalipoproteinemia

Abstract

dc:description.abstract

Familial hypobetalipoproteinemia (FHBL) and abetalipoproteinemia (ABL) are rare diseases that cause hypocholesterolemia. Studying FHBL and ABL is essential to furthering the field of cholesterol research and has provided many therapeutic targets for hypercholesterolemia. ABL is an autosomal, recessive disease caused by a mutation in MTP, a chaperone protein in the ER that helps fold nascent apoB and transfers lipids onto apoB. FHBL is an autosomal, codominant disease caused by a mutation in APOB, which usually causes a truncated apoB with loss-of-function. ABL and homozygous FHBL have the same clinical symptoms: steatorrhea, neurological dysfunction, vision problems, and non-alcoholic fatty liver. Implementing a low-fat diet routine along with vitamin supplementations will ameliorate most symptoms except for hepatic steatosis. Both ABL and FHBL carry a reduced risk of cardiovascular diseases due to the reduction of atherosclerosis. Many new therapeutic targets for hypercholesterolemia have been inspired by FHBL and ABL. Lomitapide is an MTP (microsomal triglyceride transfer protein) inhibitor that mimics ABL's mutant mechanism. Mipomersen is an apoB synthesis inhibitor, which mimics FHBL's mutant mechanism. The purpose of both drugs is to treat familial hypercholesterolemia. This literature review suggests other targets: a molecule to permanently bind apoB to MTP which mimics an FHBL mutation, a molecule to prevent PDI from binding to the large M subunit in the heterodimer MTP, and a method to truncate apoB to mimic FHBL mutations. Two new recently-discovered diseases have similar phenotypes as ABL and FHBL: PCSK9 deficiency and familial combined hypolipidemia. Both cause hypocholesterolemia. However, PCSK9 does not have the negative systemic effects such as steatorrhea and neurological dysfunction. In addition, no fatty liver develops. More research into these new diseases can contribute to the field of hypocholesterolemia, which provides new therapeutic targets for hypercholesterolemia.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2014

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chan, Jie

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/15344

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Chan, Jie. Familial hypobetalipoproteinemia and abetalipoproteinemia. masters thesis, Boston University, 2014. https://hdl.handle.net/2144/15344